Antibody Discovery & Engineering
- The state of antibody engineering for conjugation
- How discovery is being rethought for the ADC era rather than borrowed from naked-mAb programs
- How far can target diversification realistically go before validation and safety data become limiting?
- The role of AI across the discovery workflow: hype versus demonstrated impact
- Designing the antibody and the conjugate together
- Breaking the silo between discovery and downstream development
- What ‘developability’ means at the antibody stage, and how early choices cascade into CMC and clinic
- Platform thinking: can one optimized scaffold serve multiple targets and payloads?
- In-house discovery versus licensing engineered scaffolds, and what it means for differentiation